Barriers, Drivers, and Outcomes in Transitioning Patients With Inflammatory Bowel Disease From Intravenous to Subcutaneous Infliximab.

ABSTRACT:

Background

Data are limited on patients' experience of transition to subcutaneous treatment. This study aimed to determine what factors affect the decision to transition, to assess clinical outcomes and to elucidate patients' experience of transition.

Methods

This was a longitudinal, observational study carried out at University Hospital Galway, a tertiary referral center in Ireland, from November 2022 to December 2023. The drivers and barriers for patients eligible for transition were measured using a questionnaire with 21, 5-point Likert items. Clinical, biochemical, and patient-reported parameters were assessed at week 8 and week 26. Patients completed a survey at week 26 on their experience of treatment with subcutaneous Infliximab.

Results

Eighty of 144 eligible

SUBMITTER: Campion JR 

PROVIDER: S-EPMC12287920 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature